FDA Approves New Sugar Substitute — Physician’s First Watch

Medical News |
May 23, 2014

FDA Approves New Sugar Substitute

By Kristin J. Kelley

The artificial sweetener advantame has been approved for use as an all-purpose sweetener, making it the sixth sugar substitute to get the nod from the FDA.

Advantame, which was deemed safe from possible toxic effects in some 35 animal and human studies, does not raise blood sugar levels and adds few calories to food. Like aspartame, it should be avoided by people who can't metabolize phenylalanine, one of the sweetener's ingredients.

The product has no brand name yet.

Reader Comments (3)

J ROSS HESTER Other Healthcare Professional, Psychiatry, Edcom Associates Holistic Health

With he availability of Stevia, and my inclination as someone who directly experienced Aspartame's neurotoxicity, I'm extremely skeptical of even the need for Advantame. My name suggestion would be SweatorSweet?

J. Brown, MD big office in bigger building

Maybe because wannabe biochemists are always coming up with their make-believe stories about sugar substitutes, to the delight of the sugar industry.

Richard R. Thornton,M.D. Physician, Retired

How about a naming contest. I will kick it off with Sweet Sixth. Why was another sugar substitute sought? Perhaps it was discovered by accident?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
Last load event
Format: 2016-08-27 23:40:07
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.